Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2022. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5089582019 | Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | en | Synonym (core metadata concept) | Active | Only initial character case insensitive (core metadata concept) | SNOMED CT core |
| 5089583012 | Product containing precisely betamethasone (as betamethasone dipropionate) 500 microgram/1 milliliter and salicylic acid 30 milligram/1 milliliter conventional release cutaneous lotion (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Is a | Betamethasone and salicylic acid only product in cutaneous dose form | true | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has manufactured dose form | Conventional release cutaneous lotion (dose form) | true | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Plays role | Antifungal therapeutic role (role) | false | Inferred relationship | Some | ||
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has precise active ingredient | Betamethasone dipropionate | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has basis of strength substance (attribute) | Betamethasone | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has concentration strength numerator unit | mcg | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 1 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has precise active ingredient | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has basis of strength substance (attribute) | Salicylic acid (substance) | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has concentration strength numerator unit | mg | true | Inferred relationship | Some | 2 | |
| Betamethasone (as betamethasone dipropionate) 500 microgram/mL and salicylic acid 30 mg/mL cutaneous lotion | Has concentration strength denominator unit | mL | true | Inferred relationship | Some | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR